<p>Alumis Inc. (NASDAQ:ALMS - 获取免费报告) 的股价在周二的午盘交易中创下了新的 52 周高点，受到内部人士买入活动的推动。该公司股价最高达到 22.39 美元，最后交易价格为 21.98 美元，成交量为 1,607,602 股。该股票此前收盘价为 21.09 美元。</p>
<ul>
<li>3 只逆势而上的生物制药股票</li>
</ul>
<p>具体来说，主要股东 Foresite Labs, Llc 在 1 月 8 日（星期四）购买了 411,764 股该股票，交易的平均成本为每股 17.00 美元，总价值为 6,999,988.00 美元。收购完成后，内部人士直接持有该公司 5,702,536 股，估值为 96,943,112 美元。这笔交易代表了他们持股比例的 7.78% 的增加。该交易在向 SEC 提交的文件中披露，相关文件可以通过此超链接访问。此外，董事 James B. Tananbaum 在 1 月 8 日（星期四）也购买了 411,764 股该股票，平均价格为每股 17.00 美元，总交易额为 6,999,988.00 美元。购买后，该董事直接持有该公司 5,702,536 股，估值约为 96,943,112 美元。这笔交易同样代表了他们持股比例的 7.78% 的增加。有关此次购买的更多细节可在官方 SEC 披露中找到。在相关消息中，主要股东 Foresite Capital Management Vi 在 1 月 8 日（星期四）购买了 411,764 股该公司的股票，平均价格为每股 17.00 美元，总交易额为 6,999,988.00 美元。收购完成后，内部人士持有该公司 5,702,536 股，估值为 96,943,112 美元。这笔交易同样代表了他们持股比例的 7.78% 的增加。该交易在向 SEC 提交的文件中披露，相关文件可以通过此超链接访问。</p>
<h2>分析师评级变动</h2>
<p>ALMS 已经成为几份研究分析师报告的主题。Guggenheim 在 1 月 7 日（星期三）将 Alumis 的目标价从 18.00 美元上调至 32.00 美元，并给予该公司 “买入” 评级。Oppenheimer 在 1 月 6 日（星期二）重新发布了 “跑赢大盘” 评级，并对 Alumis 的股票设定了 50.00 美元的目标价。Wells Fargo &amp; Company 在 1 月 6 日（星期二）将 Alumis 的目标价从 17.00 美元上调至 39.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 12 月 29 日（星期一）的研究报告中重申了对 Alumis 股票的 “卖出（d-）” 评级。最后，Citigroup 在 1 月 6 日（星期二）的研究报告中重申了对 Alumis 股票的 “跑赢大盘” 评级。九位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 37.67 美元。</p>
<p><strong>获取我们对 ALMS 的最新分析</strong></p>
<h2>影响 Alumis 的关键故事</h2>
<p>以下是本周影响 Alumis 的关键新闻：</p>
<ul>
<li>积极情绪：主要内部人士/关联基金以每股 17.00 美元购买了 411,764 股（约 700 万美元），将其持股增加约 7.8% 至 5,702,536 股——这是董事 James B. Tananbaum / Foresite 关联实体的直接信任投票。文件：SEC 文件</li>
<li>积极情绪：多家新闻媒体报道了此次购买，增强了市场关注度，可能促成了今天的成交量激增和价格上涨压力。（示例报道）Investing.com 文章</li>
<li>积极情绪：近期分析师活动：多家机构（UBS、Oppenheimer、Guggenheim、Wells Fargo、Citi）在 1 月初发布了跑赢大盘/买入评级或上调了目标价，提升了共识情绪并支持了更高的估值。（市场评论）MarketBeat 报道</li>
<li>中性情绪：警报中的空头头寸数据基本为零/平稳，显示没有立即的挤压信号；报告的覆盖天数为 0.0，因此空头活动目前并未推动价格波动。</li>
<li>中性情绪：机构持有者（Vanguard、Samsara、Orbimed、Trium）最近调整了持股——显示出日益增长的机构兴趣，但也集中在少数大型持有者之间。机构持股</li>
<li>消极情绪：基本面风险依然存在：Alumis 在其上一个报告（11 月 13 日）中未能达到第三季度的每股收益和收入预期，尽管对管道的乐观情绪，但仍突显了执行和近期现金/收入风险。收益详情</li>
</ul>
<h2>Alumis 股票表现</h2>
<p>该公司的市值为 23.1 亿美元，市盈率为-5.46，贝塔值为-2.09。该公司的 50 日移动平均线为 9.54 美元，200 日移动平均线为 6.08 美元。</p>
<p>Alumis (NASDAQ:ALMS - 获取免费报告) 最近在 11 月 13 日（星期四）发布了季度财报。该公司报告每股收益为 (-1.06) 美元，未能达到分析师共识预期的 (-0.92) 美元，差距为 (-0.14) 美元。该业务在本季度的收入为 207 万美元，而分析师预期为 314 万美元。平均而言，卖方分析师预计 Alumis Inc.在当前财政年度将发布-8.51 的每股收益。</p>
<h2>机构投资者对 Alumis 的看法</h2>
<p>机构投资者和对冲基金最近买卖了该公司的股票。Stoneridge Investment Partners LLC 在第三季度将其在 Alumis 的持股比例提高了 8.1%。Stoneridge Investment Partners LLC 目前拥有 29,535 股该公司的股票，价值 118,000 美元，此前在上个季度增持了 2,210 股。Rhumbline Advisers 在第一季度将其在 Alumis 的持股比例提高了 21.7%。Rhumbline Advisers 目前拥有 16,543 股该公司的股票，价值 102,000 美元，此前在该期间增持了 2,949 股。Russell Investments Group Ltd. 在第三季度将其在 Alumis 的持股比例提高了 320.9%。Russell Investments Group Ltd. 目前拥有 6,419 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 4,894 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Alumis 的持股比例提高了 64.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 12,535 股该公司的股票，价值 77,000 美元，此前在该期间增持了 4,926 股。最后，BNP Paribas Financial Markets 在第三季度将其在 Alumis 的持股比例提高了 104.9%。BNP Paribas Financial Markets 目前拥有 11,770 股该公司的股票，价值 47,000 美元，此前在上个季度增持了 6,027 股。</p>
<h2>Alumis 公司简介</h2>
<p>(获取免费报告)</p>
<p>我们的使命是通过用靶向疗法替代广泛的免疫抑制来显著改善患者的生活。我们的名字 Alumis 体现了我们启迪免疫学的使命，灵感来自法语 “allumer”（照亮）和拉丁语 “immunis”（免疫系统）。我们是一家临床阶段的生物制药公司，最初专注于开发我们的两种酪氨酸激酶 2 (TYK2) 抑制剂：ESK-001，一种我们正在开发的二代抑制剂，旨在最大化靶向抑制并优化耐受性，以及 A-005，一种能够穿透中枢神经系统 (CNS) 的分子。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Alumis</li>
<li>Elon 正在将 SpaceX 上市！$100 的 IPO 前机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>股票代码揭晓：获得 “下一个 Elon Musk” 公司的 IPO 前访问权</li>
<li>这只股票获得 94 分（满分 100）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Alumis 吗？</h2>
<p>在您考虑 Alumis 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alumis 并不在名单上。</p>
<p>虽然 Alumis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ALMS

<p>Alumis Inc.（纳斯达克代码：ALMS）在内部人士大量买入活动后，达到了新的 52 周高点 22.39 美元。主要股东 Foresite Labs 以每股 17.00 美元购买了 411,764 股，增持了 7.78% 的股份。分析师们提高了目标价，Guggenheim 设定了新的目标价为 32.00 美元。尽管内部人士的购买和分析师的升级带来了积极的情绪，但 Alumis 面临挑战，因为其第三季度的盈利预期未能达标。该股票的市值为 23.1 亿美元，市盈率为-5.46</p>

<p>Alumis Inc. (NASDAQ:ALMS - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday following insider buying activity. The company traded as high as $22.39 and last traded at $21.98, with a volume of 1607602 shares traded. The stock had previously closed at $21.09.</p>
<div class="lb-trans"><p>Alumis Inc. (NASDAQ:ALMS - 获取免费报告) 的股价在周二的午盘交易中创下了新的 52 周高点，受到内部人士买入活动的推动。该公司股价最高达到 22.39 美元，最后交易价格为 21.98 美元，成交量为 1,607,602 股。该股票此前收盘价为 21.09 美元。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只逆势而上的生物制药股票</li>
</ul>
</div><p>Specifically, major shareholder Foresite Labs, Llc purchased 411,764 shares of the stock in a transaction dated Thursday, January 8th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider directly owned 5,702,536 shares in the company, valued at $96,943,112. This trade represents a 7.78% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James B. Tananbaum bought 411,764 shares of the stock in a transaction on Thursday, January 8th. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the purchase, the director directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. This trade represents a 7.78% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In related news, major shareholder Foresite Capital Management Vi bought 411,764 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the acquisition, the insider owned 5,702,536 shares of the company's stock, valued at $96,943,112. This trade represents a 7.78% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.</p>
<div class="lb-trans"><p>具体来说，主要股东 Foresite Labs, Llc 在 1 月 8 日（星期四）购买了 411,764 股该股票，交易的平均成本为每股 17.00 美元，总价值为 6,999,988.00 美元。收购完成后，内部人士直接持有该公司 5,702,536 股，估值为 96,943,112 美元。这笔交易代表了他们持股比例的 7.78% 的增加。该交易在向 SEC 提交的文件中披露，相关文件可以通过此超链接访问。此外，董事 James B. Tananbaum 在 1 月 8 日（星期四）也购买了 411,764 股该股票，平均价格为每股 17.00 美元，总交易额为 6,999,988.00 美元。购买后，该董事直接持有该公司 5,702,536 股，估值约为 96,943,112 美元。这笔交易同样代表了他们持股比例的 7.78% 的增加。有关此次购买的更多细节可在官方 SEC 披露中找到。在相关消息中，主要股东 Foresite Capital Management Vi 在 1 月 8 日（星期四）购买了 411,764 股该公司的股票，平均价格为每股 17.00 美元，总交易额为 6,999,988.00 美元。收购完成后，内部人士持有该公司 5,702,536 股，估值为 96,943,112 美元。这笔交易同样代表了他们持股比例的 7.78% 的增加。该交易在向 SEC 提交的文件中披露，相关文件可以通过此超链接访问。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>ALMS has been the topic of several research analyst reports. Guggenheim increased their price target on Alumis from $18.00 to $32.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, January 7th. Oppenheimer reissued an &#34;outperform&#34; rating and issued a $50.00 target price on shares of Alumis in a research report on Tuesday, January 6th. Wells Fargo &amp; Company boosted their price target on Alumis from $17.00 to $39.00 and gave the company an &#34;overweight&#34; rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Alumis in a research note on Monday, December 29th. Finally, Citigroup restated an &#34;outperform&#34; rating on shares of Alumis in a research report on Tuesday, January 6th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $37.67.</p>
<div class="lb-trans"><p>ALMS 已经成为几份研究分析师报告的主题。Guggenheim 在 1 月 7 日（星期三）将 Alumis 的目标价从 18.00 美元上调至 32.00 美元，并给予该公司 “买入” 评级。Oppenheimer 在 1 月 6 日（星期二）重新发布了 “跑赢大盘” 评级，并对 Alumis 的股票设定了 50.00 美元的目标价。Wells Fargo &amp; Company 在 1 月 6 日（星期二）将 Alumis 的目标价从 17.00 美元上调至 39.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 12 月 29 日（星期一）的研究报告中重申了对 Alumis 股票的 “卖出（d-）” 评级。最后，Citigroup 在 1 月 6 日（星期二）的研究报告中重申了对 Alumis 股票的 “跑赢大盘” 评级。九位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 37.67 美元。</p>
</div><p><strong>Get Our Latest Analysis on ALMS</strong></p>
<div class="lb-trans"><p><strong>获取我们对 ALMS 的最新分析</strong></p>
</div><h2>Key Stories Impacting Alumis</h2>
<div class="lb-trans"><h2>影响 Alumis 的关键故事</h2>
</div><p>Here are the key news stories impacting Alumis this week:</p>
<div class="lb-trans"><p>以下是本周影响 Alumis 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Major insider/affiliated fund bought 411,764 shares (~$7.0M) at $17.00 per share, increasing their stake by ~7.8% to 5,702,536 shares — a direct vote of confidence from Director James B. Tananbaum / Foresite-affiliated entities. Filing: SEC Filing</li>
<li>Positive Sentiment: Multiple news outlets reported the purchase, amplifying market attention and likely contributing to today’s volume spike and upward price pressure. (Example coverage) Investing.com article</li>
<li>Positive Sentiment: Recent analyst activity: several firms (UBS, Oppenheimer, Guggenheim, Wells Fargo, Citi) have issued Outperform/Buy or raised price targets in early January, lifting consensus sentiment and supporting higher valuations. (Market commentary) MarketBeat coverage</li>
<li>Neutral Sentiment: Short interest data in the alert is effectively zero/flat and shows no immediate squeeze signal; days-to-cover reported as 0.0, so short activity is not currently driving price action.</li>
<li>Neutral Sentiment: Institutional holders (Vanguard, Samsara, Orbimed, Trium) have recently adjusted stakes — shows growing institutional interest but also concentration among a few large holders. Institutional holdings</li>
<li>Negative Sentiment: Fundamental risk remains: Alumis missed Q3 EPS and revenue estimates in its last report (Nov. 13), underscoring execution and near-term cash/revenue risk despite optimism on pipeline. Earnings detail</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：主要内部人士/关联基金以每股 17.00 美元购买了 411,764 股（约 700 万美元），将其持股增加约 7.8% 至 5,702,536 股——这是董事 James B. Tananbaum / Foresite 关联实体的直接信任投票。文件：SEC 文件</li>
<li>积极情绪：多家新闻媒体报道了此次购买，增强了市场关注度，可能促成了今天的成交量激增和价格上涨压力。（示例报道）Investing.com 文章</li>
<li>积极情绪：近期分析师活动：多家机构（UBS、Oppenheimer、Guggenheim、Wells Fargo、Citi）在 1 月初发布了跑赢大盘/买入评级或上调了目标价，提升了共识情绪并支持了更高的估值。（市场评论）MarketBeat 报道</li>
<li>中性情绪：警报中的空头头寸数据基本为零/平稳，显示没有立即的挤压信号；报告的覆盖天数为 0.0，因此空头活动目前并未推动价格波动。</li>
<li>中性情绪：机构持有者（Vanguard、Samsara、Orbimed、Trium）最近调整了持股——显示出日益增长的机构兴趣，但也集中在少数大型持有者之间。机构持股</li>
<li>消极情绪：基本面风险依然存在：Alumis 在其上一个报告（11 月 13 日）中未能达到第三季度的每股收益和收入预期，尽管对管道的乐观情绪，但仍突显了执行和近期现金/收入风险。收益详情</li>
</ul>
</div><h2>Alumis Stock Performance</h2>
<div class="lb-trans"><h2>Alumis 股票表现</h2>
</div><p>The company has a market capitalization of $2.31 billion, a PE ratio of -5.46 and a beta of -2.09. The company's fifty day moving average is $9.54 and its 200-day moving average is $6.08.</p>
<div class="lb-trans"><p>该公司的市值为 23.1 亿美元，市盈率为-5.46，贝塔值为-2.09。该公司的 50 日移动平均线为 9.54 美元，200 日移动平均线为 6.08 美元。</p>
</div><p>Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. On average, sell-side analysts expect that Alumis Inc. will post -8.51 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Alumis (NASDAQ:ALMS - 获取免费报告) 最近在 11 月 13 日（星期四）发布了季度财报。该公司报告每股收益为 (-1.06) 美元，未能达到分析师共识预期的 (-0.92) 美元，差距为 (-0.14) 美元。该业务在本季度的收入为 207 万美元，而分析师预期为 314 万美元。平均而言，卖方分析师预计 Alumis Inc.在当前财政年度将发布-8.51 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Alumis</h2>
<div class="lb-trans"><h2>机构投资者对 Alumis 的看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the business. Stoneridge Investment Partners LLC lifted its position in shares of Alumis by 8.1% in the third quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company's stock valued at $118,000 after acquiring an additional 2,210 shares in the last quarter. Rhumbline Advisers raised its stake in Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after purchasing an additional 2,949 shares during the period. Russell Investments Group Ltd. lifted its holdings in Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company's stock worth $26,000 after purchasing an additional 4,894 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Alumis by 64.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock worth $77,000 after purchasing an additional 4,926 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Alumis by 104.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company's stock valued at $47,000 after buying an additional 6,027 shares in the last quarter.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该公司的股票。Stoneridge Investment Partners LLC 在第三季度将其在 Alumis 的持股比例提高了 8.1%。Stoneridge Investment Partners LLC 目前拥有 29,535 股该公司的股票，价值 118,000 美元，此前在上个季度增持了 2,210 股。Rhumbline Advisers 在第一季度将其在 Alumis 的持股比例提高了 21.7%。Rhumbline Advisers 目前拥有 16,543 股该公司的股票，价值 102,000 美元，此前在该期间增持了 2,949 股。Russell Investments Group Ltd. 在第三季度将其在 Alumis 的持股比例提高了 320.9%。Russell Investments Group Ltd. 目前拥有 6,419 股该公司的股票，价值 26,000 美元，此前在上个季度增持了 4,894 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Alumis 的持股比例提高了 64.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 12,535 股该公司的股票，价值 77,000 美元，此前在该期间增持了 4,926 股。最后，BNP Paribas Financial Markets 在第三季度将其在 Alumis 的持股比例提高了 104.9%。BNP Paribas Financial Markets 目前拥有 11,770 股该公司的股票，价值 47,000 美元，此前在上个季度增持了 6,027 股。</p>
</div><h2>Alumis Company Profile</h2>
<div class="lb-trans"><h2>Alumis 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words &#34;allumer&#34;-French for illuminate-and &#34;immunis&#34;-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.</p>
<div class="lb-trans"><p>我们的使命是通过用靶向疗法替代广泛的免疫抑制来显著改善患者的生活。我们的名字 Alumis 体现了我们启迪免疫学的使命，灵感来自法语 “allumer”（照亮）和拉丁语 “immunis”（免疫系统）。我们是一家临床阶段的生物制药公司，最初专注于开发我们的两种酪氨酸激酶 2 (TYK2) 抑制剂：ESK-001，一种我们正在开发的二代抑制剂，旨在最大化靶向抑制并优化耐受性，以及 A-005，一种能够穿透中枢神经系统 (CNS) 的分子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Alumis</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>This stock gets a 94 out of 100</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Alumis</li>
<li>Elon 正在将 SpaceX 上市！$100 的 IPO 前机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>股票代码揭晓：获得 “下一个 Elon Musk” 公司的 IPO 前访问权</li>
<li>这只股票获得 94 分（满分 100）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alumis Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Alumis 吗？</h2>
</div><p>Before you consider Alumis, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Alumis 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alumis 并不在名单上。</p>
</div><p>While Alumis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alumis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Alumis（纳斯达克股票代码：ALMS）因内部人士的买入活动达到一年新高